Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma

NCT06044311 · clinicaltrials.gov ↗

PHASE2

Phase

SUSPENDED

Status

30

Enrollment

OTHER

Sponsor class

Stopped Major revisions due

Conditions

Adenocarcinoma Esophagus
Locally Advanced Adenocarcinoma
Siewert Type I Adenocarcinoma of Esophagogastric Junction
Siewert Type II Adenocarcinoma of Esophagogastric Junction

Interventions

DRUG: Vactosertib
DRUG: Standard of Care Preoperative Therapy

Sponsor

Melissa Lumish